Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 10,181 | 1,458 | 864 | 889 | 892 |
| Gross Profit | 10,181 | 1,458 | 864 | 889 | 892 |
| Operating Expenses | 127,450 | 131,706 | 155,628 | 132,948 | 230,216 |
| Operating Income | -117,269 | -130,248 | -154,764 | -132,059 | -229,324 |
| Other Income | 27,075 | 8,156 | 24,765 | 26,237 | 22,067 |
| Pre-tax Income | -90,194 | -122,092 | -129,999 | -105,822 | -207,257 |
| Income Tax | 960 | 839 | 614 | 619 | 1,292 |
| Net Income Continuous | -91,154 | -122,931 | -130,613 | -106,441 | -208,549 |
| Net Income | $-91,154 | $-122,931 | $-130,613 | $-106,441 | $-208,549 |
| EPS Basic Total Ops | -0.94 | -1.28 | -1.32 | -1.17 | -2.40 |
| EPS Basic Continuous Ops | -0.94 | -1.28 | -1.32 | -1.17 | -2.40 |
| EPS Diluted Total Ops | -0.94 | -1.28 | -1.32 | -1.17 | -2.40 |
| EPS Diluted Continuous Ops | -0.94 | -1.28 | -1.32 | -1.17 | -2.40 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.28 | -1.37 | -1.17 | -1.29 |
| EBITDA(a) | $-112,989 | $-125,929 | $-149,103 | $-127,626 | $-224,675 |